🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

One of the best reviews this year on pharmacological targeting of KRAS - direct or indirect - is written by Norbert Kraut Sandra Misale Daniel Gerlach Marco Hofmann in Cancer Discovery - #OpenAccess & worth reading! aacrjournals.org/cancerdiscover…

A new commentary online NEJM by Piro Lito Memorial Sloan Kettering Cancer Center KRAS Oncoprotein Signaling in Cancer The commentary summarizes the implications of two back to back Science Magazine studies from Channing Der @klomp2je and the other Klomp (Jeffrey) These studies highlight the importance

A success for our GI Oncology #SiteDiseaseGroup Sylvester Comprehensive Cancer Center, with Bach Ardalan leading this Clinical Cancer Research📖on distinct molecular➕clinical features of #KRAS G12 mutations, esp KRAS G12R, in #PancreaticCancer #pancsm! Builds on ongoing 🫱🏽‍🫲🏾 w/ Caris Life Sciences POA aacrjournals.org/clincancerres/…

Cynthia #TumorBoardTuesday David S. Hong MD george demetri Journal of Clinical Oncology #tumorBoardTuesday For KRAS pts, this may be relevant research nature.com/articles/s4159…

ESOPEC, a large randomized trial involving patients with resectable esophageal cancer, showed that perioperative chemotherapy improved overall survival as compared with preoperative chemoradiotherapy. Full trial results: nej.md/4apWlo5 Editorial: Multimodal Treatment

Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic? Pan-RAS inhibitor shows early/deep molecular response (and 36% response rate) for G12X mutated pancreatic cancer. (Significant AEs: rash, diarrhea, nausea, vomiting) dailynews.ascopubs.org/do/pan-ras-inh…

Great data for pts w/ 2+ line met anal cancer for pembrolizumab+ficerafusp alfa (EGFR/TGFb bispecific) -ORR 29% & 41% 12-mo DFS=benefit in liver mets+pCR for exceptional responder ! Exciting signal as combination immuotherapy in anal cancer! MD Anderson Cancer Center #endcancer Bicara Therapeutics

Results from the phase II study of zenocutuzumab in #NRG1 fusion+ cancers now NEJM. RR 30% with DOR 11.1m, PFS 6.8m, favorable safety profile. These cancers do not respond well to standard therapy. Zeno FDA approved for NSCLC, pancreatic cancer. nejm.org/doi/full/10.10…

Paper is out!!! FDA approved for NRG1 Fusion+ Non-Small Cell #LungCancer and #PancreaticCancer Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer nejm.org/doi/full/10.10… Alison Schram Stephen V Liu, MD Tanios Bekaii-Saab, MD Kim Reiss Binder (Kim Reiss) Merus NEJM Memorial Sloan Kettering Cancer Center Georgetown Lombardi

Pancreatic cancer remains one of the toughest cancers to treat. But newer therapies entering clinical trials are giving doctors hope. on.wsj.com/4hWo6Yo

We are gearing up for the 6th Annual Patient and Family Forum on Saturday, March 29th, with new Beyond CRC hats! It is not too late to register for the event! #ColorectalCancer #CRC #DanaFarber

Congratulations to Linghua Wang, MD, PhD Guangsheng Pei Jimin Min and all our exceptional collaborators at MD Anderson Cancer Center & beyond for today's study in nature on spatial mapping of transcriptomic plasticity in metastatic #PancreaticCancer The full text link is rdcu.be/ei0Y2

Congratulations to Will Freed Pastor Hale Family Center For Pancreatic Cancer Research on his foundational Science Magazine paper!! Totally transforms the landscape of #PancreaticCancer tumor antigens. Jacks Lab Break Through Cancer Lustgarten Foundation science.org/doi/10.1126/sc…

Pancreatic cancer cells express cryptic peptides shared across patients that may be therapeutic targets, according to new research in Science. 📄: scim.ag/4mmkSQz #SciencePerspective: scim.ag/4kgEKCH

Presented at #ASCO25: The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600E–mutated colorectal cancer. Full BREAKWATER phase 3 trial results: nej.md/3ScDaWC

Immediately practice changing and deserves discussion with each pt! The first RCT supporting structured exercise after adjuvant therapy for colon cancer. It’s striking how exercise improves survival, especially compared to drugs with FDA approval and payer support. 👀 #ASCO25

No doubt the best GI Onc division on the planet! So grateful to work with brilliant, kind, and visionary colleagues #ASCO25 Dana-Farber Dana-Farber News Dana-Farber's Young-Onset Colorectal Cancer Center ASCO

🔥NeoPancOne🇨🇦 ➡️mFFX in resectable PDAC ➡️exploring GATA6&subtypes ➡️mEFS &OS 16.3 &34.2mths ➡️1yr EFS 90% in GATA6 hi vs 50% lo ➡️1yr OS classical 95% vs.57% basal-like ⭐️Time to subtype upfront in all PDAC recognising plasticity OncoAlert #ASCO25 Ontario Institute for Cancer Research (OICR) Princess Margaret Cancer Centre

Excellent work by Dana-Farber colleague Asaf Maoz presenting his #ASCO25 oral abstract: Sensitivity of age and family history (FH) criteria for determining pancreatic cancer (PC) surveillance (PCS) eligibility among individuals with hereditary PC risk. meetings.asco.org/2025-asco-annu…

Final COMPASS trial data advanced #PDAC ➡️268 WGS& 253RNA-seq ➡️basal-like& hi GRIm-S ⬇️OS, both unique TME inc CD8 variation,NB primaries vs mets ➡️LTS :HRD, KRAS WT ➡️KRAS major enriches basal, >type II DM ➡️LAPC≠intact SMAD4 ➡️47% receive 2nd line tx nature.com/articles/s4146…